PTGEF Stock UPDATES Portage Biotech Inc. (PTGEF) 0.1430 08/30/2014
Post# of 273330
Posted On: 08/30/2014 2:54:27 AM
Portage Biotech Inc. (PTGEF) 0.1430 $PTGEF
Portage's Biohaven granted United States patent for glutamate agents in the treatment of mental disorders
PR Newswire - Wed Aug 06, 8:00AM CDT
Intellectual property licensed from Yale University protects the use of certain glutamate modulating agents in the treatment of Generalized Anxiety Disorder (GAD) until 2029
Portage announces successful validation of its new proprietory cell permeable peptide platform technology
PR Newswire - Mon Jul 14, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, Canadian Stock Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary Portage Pharmaceuticals Ltd. (PPL) has successfully validated a new proprietary cell permeable peptide platform technology derived from human genes. This proprietary platform technology has been shown to efficiently deliver an active pharmacological agent or cargo into a cell without disrupting the cell membrane.
Critical Outcome Technologies Identifies Experienced Partner for Clinical Development of COTI-2
Marketwire - Wed Feb 26, 8:31AM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a non-binding letter of intent ("LOI" to form a joint venture with Portage Biotech Inc. ("Portage" , a British Virgin Island incorporated public company, listed and traded on the Canadian Securities Exchange ("PTB.U" , and on NASDAQ and the OTC ("PTGEF" to fund and direct the Phase 1 development of the Company's clinical oncology candidate, COTI-2.
Portage reports third quarter financial results and provides updates
PR Newswire - Tue Feb 25, 12:06PM CST
Portage Biotech Inc. ("Portage" (OTCQB: PTGEF, CNSX: PBT.U), today filed its unaudited consolidated financials and related management discussion & analysis for the three and nine months ended December 31, 2013. These can be viewed on our website, www.portagebiotech.com.
Portage acquires majority interest in Biohaven Pharmaceutical Holding Company Limited
PR Newswire - Mon Jan 06, 4:00PM CST
Portage Biotech Inc. ("Portage" (OTCQB: PTGEF, CNSX: PBT.U), is pleased to announce that it has acquired approximately 54% equity in Biohaven Pharmaceutical Holding Company Limited ("Biohaven" , a private corporation formed under the laws of the British Virgin Islands, for $3.5 million, payable as $1.75 million upfront and the balance in three installments over the next eleven months.
Portage launches new website and provides update on its R&D Activities
PR Newswire - Tue Dec 17, 8:28AM CST
Portage Biotech Inc. ("the Company" (OTCQB: PTGEF, CNSX: PBT.U) ("Portage" is pleased to announce the launch of its new web site, www.portagebiotech.com, which goes live today.
Portage's Biohaven granted United States patent for glutamate agents in the treatment of mental disorders
PR Newswire - Wed Aug 06, 8:00AM CDT
Intellectual property licensed from Yale University protects the use of certain glutamate modulating agents in the treatment of Generalized Anxiety Disorder (GAD) until 2029
Portage announces successful validation of its new proprietory cell permeable peptide platform technology
PR Newswire - Mon Jul 14, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, Canadian Stock Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary Portage Pharmaceuticals Ltd. (PPL) has successfully validated a new proprietary cell permeable peptide platform technology derived from human genes. This proprietary platform technology has been shown to efficiently deliver an active pharmacological agent or cargo into a cell without disrupting the cell membrane. Critical Outcome Technologies Identifies Experienced Partner for Clinical Development of COTI-2
Marketwire - Wed Feb 26, 8:31AM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a non-binding letter of intent ("LOI" to form a joint venture with Portage Biotech Inc. ("Portage" , a British Virgin Island incorporated public company, listed and traded on the Canadian Securities Exchange ("PTB.U" , and on NASDAQ and the OTC ("PTGEF" to fund and direct the Phase 1 development of the Company's clinical oncology candidate, COTI-2. Portage reports third quarter financial results and provides updates
PR Newswire - Tue Feb 25, 12:06PM CST
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, CNSX: PBT.U), today filed its unaudited consolidated financials and related management discussion & analysis for the three and nine months ended December 31, 2013. These can be viewed on our website, www.portagebiotech.com. Portage acquires majority interest in Biohaven Pharmaceutical Holding Company Limited
PR Newswire - Mon Jan 06, 4:00PM CST
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, CNSX: PBT.U), is pleased to announce that it has acquired approximately 54% equity in Biohaven Pharmaceutical Holding Company Limited ("Biohaven" , a private corporation formed under the laws of the British Virgin Islands, for $3.5 million, payable as $1.75 million upfront and the balance in three installments over the next eleven months. Portage launches new website and provides update on its R&D Activities
PR Newswire - Tue Dec 17, 8:28AM CST
Portage Biotech Inc. ("the Company"
(OTCQB: PTGEF, CNSX: PBT.U) ("Portage" is pleased to announce the launch of its new web site, www.portagebiotech.com, which goes live today. 
(0)
(0)